Concise Prescribing Info
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Osteoarthritis; Rheumatoid arthritis As conventional tab/cap: 600-1,000 mg/day. As extended-release tab: 400-1,000 mg once daily. Acute pain As conventional tab/cap: 200-400 mg 6-8 hrly. Max: 1,000 mg/day.
Dosage Details
Acute pain
Adult: As conventional tab/cap: 200-400 mg 6-8 hrly. Max: 1,000 mg daily.

Osteoarthritis, Rheumatoid arthritis
Adult: As conventional tab/cap: 600-1,000 mg daily in divided doses, adjust according to response. As extended-release tab: 400-1,000 mg once daily, according to response.
Should be taken with food. Take w/ or immediately after meals.
Hypersensitivity to etodolac or other NSAIDs. GI bleeding or perforation related to previous NSAID therapy, severe heart failure, active or history of peptic ulcer disease. Treatment of perioperative pain in the setting of CABG. 3rd trimester of pregnancy.
Special Precautions
Patient w/ CHF, uncontrolled HTN, ischaemic heart disease, peripheral arterial disease, cerebrovascular disease and those w/ risk factors for CV disease (e.g. HTN, hyperlipidaemia, DM, smoking); bronchial asthma, history of GI disease (e.g. ulcerative colitis, Crohn’s disease). Renal or hepatic impairment. Pregnancy and lactation.
Adverse Reactions
Oedema, HTN, cardiac failure, nausea, epigastric pain, diarrhoea, indigestion, heartburn, flatulence, abdominal pain, constipation, vomiting, ulcerative stomatitis, dyspepsia, haematemesis, melaena, rectal bleeding, exacerbation of colitis, vasculitis, headaches, dizziness, abnormal vision, pyrexia, drowsiness, tinnitus, rash, pruritus, fatigue, depression, insomnia, confusion, paraesthesia, tremor, weakness, dyspnoea, palpitations, bilirubinuria, hepatic function abnormalities, jaundice, urinary frequency, Crohn’s disease, photosensitivity, asthma, nephritis, anaemia.
Potentially Fatal: Serious CV thrombotic events (e.g. stroke, MI), GI effects (e.g. perforation, bleeding and ulceration), fulminant hepatitis, liver necrosis, hepatic failure. Very rarely, serious skin reactions (e.g. Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis).
PO: C (Avoid use during 3rd trimester or near delivery.)
Patient Counseling Information
This drug may cause dizziness, drowsiness, fatigue or abnormal vision, if affected, do not drive or operate machinery.
Monitor for signs and symptoms of GI bleeding and hepatic dysfunction; renal function, BP at the beginning of therapy and periodically; CBC and chemistry profile (long-term therapy).
Symptoms: Lethargy, drowsiness, nausea, vomiting, epigastric pain, GI bleeding, coma, HTN, acute renal failure, resp depression. Management: Symptomatic and supportive treatment. Perform emesis and/or administer activated charcoal or osmotic cathartic w/in 4 hr of ingestion.
Drug Interactions
May increase the effect of lithium, warfarin and methotrexate. Increased risk of adverse effect w/ aspirin or other NSAIDs. May reduce the effect of diuretics, mifepristone and antihypertensives. Increased risk of nephrotoxicity w/ ciclosporin, diuretics and tacrolimus, Increased risk of GI bleeding w/ SSRIs, anti-platelets and corticosteroids. Increased risk of convulsions w/ quinolone antibiotics. Increased risk of haematological toxicity when given w/ zidovudine. May exacerbate cardiac failure, reduce GFR and increase serum level w/ of cardiac glycoside.
Food Interaction
May decrease GI upset and serum peak levels when taken w/ food. Alcohol enhances gastric mucosal irritation.
Lab Interference
False-positive reaction for urinary bilirubin and ketones.
Description: Etodolac is an NSAID derived from pyrano-indoleacetic acid which inhibits cyclooxygenase 2 (COX-2), resulting in decreased prostaglandin precursor formation.
Onset: Analgesia: Approx 30 min (conventional preparation). Arthritis (chronic use): W/in 2 wk.
Duration: Mean range: 4-6 hr.
Absorption: Rapidly absorbed. Bioavailability: ≥80%. Time to peak plasma concentration: W/in approx 2 hr.
Distribution: Distributed to synovial fluid. Volume of distribution: Approx 390 mL/kg. Plasma protein binding: >99%, primarily to albumin.
Metabolism: Extensively metabolised in the liver to hydroxylated metabolites and etodolac glucuronide; hydroxylated metabolites undergo further glucuronidation.
Excretion: Mainly via urine (73%); faeces (16%).
Chemical Structure

Click on icon to see table/diagram/image
Store between 20-25˚C.
ATC Classification
M01AB08 - etodolac ; Belongs to the class of acetic acid derivatives and related substances of non-steroidal antiinflammatory and antirheumatic products.
Disclaimer: This information is independently developed by MIMS based on Etodolac from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in